Moreover, G6pc expression negatively correlated with circulating miR-494 levels and tumor size, demonstrating the crucial role of miR-494/G6pc axis in sorafenib resistance in preclinical models (Fig. 6H-J). This evidence concerns the gene G6PC1 and neoplasm.